|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 October 2017 |
|
Main ID: |
NCT02079519 |
|
Date of registration:
|
04/03/2014 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma
|
|
Scientific title:
|
Bevacizumab as Treatment for Patients With Relapsed/Refractory Multiple Myeloma |
|
Date of first enrolment:
|
May 2006 |
|
Target sample size:
|
10 |
|
Recruitment status: |
Terminated |
|
URL:
|
https://clinicaltrials.gov/show/NCT02079519 |
|
Study type:
|
Interventional |
|
Study design:
|
|
|
Phase:
|
Phase 2
|
|
|
Countries of recruitment
|
|
Austria
| | | | | | | |
|
Contacts
|
|
Name:
|
Clinical Trials |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Hoffmann-La Roche |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Adult patients, 19-75 years of age
- Multiple myeloma.
- Progressive disease after at least 2 lines of prior therapy.
Exclusion Criteria:
- Non-secretory myeloma.
- History of malignancy, other than squamous cell cancer, basal cell cancer, or cancer
in situ of the cervix within the last 5 years.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to study treatment start.
- Clinically significant cardiac disease.
Age minimum:
19 Years
Age maximum:
75 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Multiple Myeloma
|
|
Intervention(s)
|
|
Drug: Bevacizumab
|
|
Primary Outcome(s)
|
|
Percentage of Participants With a Complete Response or a Partial Response
[Time Frame: Baseline to the end of the study (up to 1 year)]
|
|
Secondary Outcome(s)
|
|
Overall Survival
[Time Frame: Baseline to the end of the study (up to 1 year)]
|
|
Progression-free Survival
[Time Frame: Baseline to the end of the study (up to 1 year)]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|